| Symbol | EMBT |
|---|---|
| Name | EMBER THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 10022 United States NY 135 East 57th Street 24th Floor |
| Telephone | (646) 612-4000 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | US |
| Incorporated On | 1987 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | EisnerAmper LLP; |
| Audit Status | NOT AVAILABLE |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0000813389 |
| Description | Ember Therapeutics is a biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 (BMP-7) and related family of BMPs, mutants, variants, novel formulations, and delivery technologies to develop regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome. Additional info from OTC: |
Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: EMBER THERAPEUTICS INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: EMBER THERAPEUTICS INC.
Read more